Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2003-10-08
2009-02-17
Wilson, James O. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
active
07491718
ABSTRACT:
Compounds having methionine aminopeptidase-2 inhibitory (MetAP2) are described. Also described are pharmaceutical compositions comprising the compounds, methods of treatment using the compounds, methods of inhibiting angiogenesis, and methods of treating cancer.
REFERENCES:
patent: 2335221 (1943-11-01), Ewins et al.
patent: 3162684 (1964-12-01), Frick et al.
patent: 5929097 (1999-07-01), Levin et al.
patent: 6207704 (2001-03-01), Liu et al.
patent: 6335334 (2002-01-01), Schindler et al.
patent: 2004/0019113 (2004-01-01), Jozefiak et al.
patent: 272 351 (2004-08-01), None
patent: 686 644 (1940-01-01), None
patent: 2001-240581 (2001-09-01), None
patent: 98/16503 (1998-04-01), None
patent: 98/16506 (1998-04-01), None
patent: 98/16514 (1998-04-01), None
patent: 98/16520 (1998-04-01), None
Griffith et al., “Methionine aminopeptidase (type 2) is the common target for angiogenesis inhibitors AGM-1470 and ovalicin,” Chemistry & Biology 4(5):461-471 (1997).
Hodgson et al., “Reactions of Aromatic Nitro-compounds with Alkaline Sulphides.” J. Chem. Soc. 1187 (1949).
Showalter et al., “Concise syntheses of the novel 1H-pyrrolo[3,2-g]quinazoline ring system and its [2,3-f] angular isomer,” J. Org. Chem. 61:1155-1158 (1996).
Sin et al., “The anti-angiogenic agent fumagillin covalently binds and inhbits the methionine aminopeptidase, MetAP-2,” Proc. Natl. Acad. Sci. USA 94:6099-6103 (1997).
Tilley et al., “Synthesis of 5-alkoxyanthranilic acids,” Org. Prep. Proc. Int. 13(3-4):189-196 (1981).
Tomioka et al., “Studies on aromatic nitro compounds. V. A simple one-pot preparation of o-aminoaroyInitriles from some aromatic nitro compounds,” Chem. Pharm. Bull. 33(4):1360-1366 (1985).
J. Med. Chem. 33(5):1312-1329 (1990) XP002271724.
J. Org. Chem. 53(7):1380-1383 (1988) XP002271725.
Bull. Chem. Soc. Jpn. 40:2844-2847 (1967) XP002271726.
J. Chem. Soc. Perkin Trans. I 1602-1605 (1973) XP002271727.
Synthesis, 4:280-282 (1989) XP002271728.
Chem. Ber. 76:128-134 (1943) XP002271729.
J. Am. Chem. Soc. 67:1711 (1945) XP002271730.
Nippon Kagaku Kaishi 723-727 (1978) XP002271731.
J. Chem. Soc. 961-966 (1950) XP002271732.
Synthesis 6:487-489 (1981) XP002271733.
J. Med. Chem. 24(9):1097-1099 (1981) XP002271734.
Heterocycl. Chem. 30(6):1613-1622 (1993) XP002271736.
Chem. Heterocycl. Compd. 8:557-561 (1972) XP002271737.
Chem. Heterocycl. Compd. 7:964-967 (1971) XP002271738.
Chem. Heterocycl. Compd. 8:1212-1215 (1972) XP002271739.
Chem. Pharm. Bull. 41(5):894-906 (1993) XP002271740.
J. Org Chem. 38:1512-1517 (1973) XP002271741.
J. Chem. Soc. Perkin Trans. I 2313-2318 (1973) XP002271742.
Tetrahedron 44(5):1465-1476 (1988) XP002271743.
J. Am. Chem. Soc. 109(21):6491-6502 (1987) XP002271744.
JP 2001-240581 XP002271745.
Proceedings of the National Academy of Sciences of the United States of America 99(15):10066-10071 (2002) XP002271723.
Ba-Maung Nwe Y.
Barnes David M.
Comess Kenneth M.
Erickson Scott A.
Fidanze Steve D.
Abbott Laboratories
Donner B. Gregory
Sackey Ebenezer
Wilson James O.
LandOfFree
Sulfonamides having antiangiogenic and anticancer activity does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Sulfonamides having antiangiogenic and anticancer activity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sulfonamides having antiangiogenic and anticancer activity will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4068408